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Acquired factor VIII deficiency is very rare, often fatal. It is associated with pregnancy, 
autoimmune diseases, malignancy, and drugs, although no underlying cause is found in 
50%. A 49-year-old male was referred with right shoulder bruising. The coagulation test 
showed a prolonged activated partial thromboplastin time. The factor VIII level was less 
than 1%, and the factor VIII inhibitor antibody titer was 246 Bethesda units/mL. The find-
ings were compatible with acquired factor VIII deficiency. He had consumed the dried 
gallbladder of a cobra, Naja naja, for two weeks, it contained venom. After the initial treat-
ment with factor VIII, he did not take supplemental coagulation factor VIII. The patient 
was readmitted with left forearm swelling. He lost consciousness suddenly and brain 
computed tomography (CT) revealed a subdural hematoma. Despite administering re-
combinant factor VII, his bleeding was not controlled and he died.
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INTRODUCTION
  Acquired factor VIII deficiency is caused by the develop-
ment of autoantibodies directed against circulating coagu-
lation factor VIII, which inhibits its function [1, 2]. It is 
very uncommon, often life-threatening [3]. It may be asso-
ciated with pregnancy, the postpartum period, autoimmune 
conditions, drugs, lymphoproliferative disorders, or malig-
nancies. In approximately half of the diagnosed cases, no 
underlying disease is detected [3-6]. We report a rare case 
of subdual hemorrhage in a man, who acquired factor VIII 
inhibitors and developed coagulopathy after consuming toxin 
of the cobra, Naja naja. This is the first report of acquired 
factor VIII inhibitor developed after Cobratoxin intake.
CASE REPORT
  A 49-year-old male was admitted with a 10-day history 
of subcutaneous hemorrhage of the right shoulder (Fig. 1) 
and left thigh. His medical history included diabetes mellitus 
and hypertension. The patient was being treated with los-
artan 50 mg/day for hypertension and metformin 500 mg 
twice a day for diabetes. He had eaten 10 g of dried gall 
bladder of a cobra, Naja naja in Thailand one month ago. 
The gallbladder contained venom, and had been manufac-
tured using an unknown process. His family history was 
negative for hemorrhagic disorder.
  His vital signs included blood pressure of 130/70 mmHg 
and heart rates of 100/min. Laboratory test showed a pro-
longed activated partial thromboplastin time (aPTT) exceed-
ing 120 seconds (normal range, 30-47 seconds), not corrected 
with plasma mixing test. His prothrombin time was 10 sec-
onds (normal range, 10-13 seconds), the level of FDP was 
11.71 ug/mL (normal range, below 5 ug/mL), and D-dimer 
was 3.42 ug/mL (normal range, below 1.3 ug/mL). His hemo-
globin was 7.0 g/dL and platelet count was 323×10
9/L. The 
factor VIII level was less than 1%, and his factor VIII inhibitor 
antibody titer was 246 Bethesda units/mL (normal range, Korean J Hematol 2010;45:205-7.
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Fig. 1. Subcutaneous hemorrhage of the right shoulder, upper arm, and
axilla on admission. Fig. 2. The T1-weighted image of magnetic resonance imaging of the 
left thigh shows an intramuscular hematoma (4.4 cm arrow) of the left
vastus medialis.
Fig. 3. Axial brain computed tomography shows a left subdural hema-
toma.
0-0.7 Bethesda units/mL). Lupus anticoagulant antibody, an-
ti-nuclear antibody and anti-phospholipid antibody were 
negative. The level of factor XI and factor XII was normal. 
His chest and abdominopelvic CT scan were negative for 
malignancy. He was diagnosed with acquired factor VIII 
deficiency. Magnetic resonance imaging (MRI) of the thigh 
showed hematomas in the left vastus medialis muscle (Fig. 
2). The patient was treated with an intravenous infusion 
of factor VIII 3,000 U (50 U/kg) every 8 hours. One month 
after treatment, the patient’s symptoms improved, but his 
factor VIII inhibitor antibody titer was still high (147 
Bethesda units/mL).
  One year later, the patient presented with swelling of 
the left forearm. He had an aPTT exceeding 120 seconds 
due to the presence of high titers of factor VIII inhibitor 
(217 Bethesda units/mL). Ten days after admission, he lost 
consciousness suddenly. Brain CT scan revealed a mixed 
subacute subdural hematoma in the left fronto-temporo-occi-
pital areas (Fig. 3) and recombinant factor VII was infused 
at a dose of 360 KIU/day. Despite treatment, the patient’s 
bleeding worsened. Two weeks later, multifocal subara-
chnoid hemorrhages and intracranial hemorrhages in both 
cerebral hemispheres were revealed. He subsequently died.
DISCUSSION
  Acquired factor VIII deficiency is rare, but life-threatening. 
It results from the development of inhibitors, that typically 
interfere with the coagulant properties of factor VIII [1, 
2, 7]. The estimated annual incidence is between 1.3 and 
1.5 million per year [1]. The clinical picture is characterized 
by spontaneous and often sudden onset of severe hemorrhage 
in a patient with no bleeding history. More than 80% of 
patients have hemorrhages into the skin, muscles or soft 
tissues, and mucous membranes [2]. Mortality rates range 
from 9 to 22% [8]. Up to 30% of patients resolve without 
treatment. However, the spontaneous disappearance of in-
hibitors is unpredictable and may occur over many years 
[8]. The prognosis is worse in patients with higher inhibitor 
titers [9]. Our patient had a persistently high titer of factor 
VIII inhibitor antibody. For a better prognosis, eradication 
of the inhibitor and maintenance of normal level of clotting 
factor VIII are important [10].
  The therapeutic strategy is to stop the hemorrhage and 
reduce the autoantibody levels. Bypassing products currently 
available for bleeding control are recombinant activated fac-
tor Ⅶ (rFVIIa) and plasma-derived activated prothrombin 
complex concentrate (aPCC) [11]. In patients with a high 
inhibitor titer and severe hemorrhages, the extracorporeal 
removal of the autoantibody by therapeutic plasmapheresis 
can be used before factor concentrate treatment [11]. There 
are two case reports in Korea which were successfully treated 
with combination therapy that included therapeutic plasma-
pheresis [12]. Once hemostasis is achieved, autoantibody 
eradication is the second major goal of acquired hemophilia Korean J Hematol 2010;45:205-7.
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therapy. The inhibitor may also be eradicated with im-
munosuppressive agents, including corticosteroids and cyto-
toxic drugs, such as cyclophosphamide, azathioprine, 6-mer-
captopurine, and vincristine. 
  We report the first case of acquired factor VIII deficiency 
in a patient, who suffered from coagulopathy after consuming 
the dried gallbladder of a cobra. Coagulopathy is a significant 
cause of both morbidity and mortality in snakebite patients 
[13, 14]. A wide variety of venom components can act as 
procoagulants, activating the coagulation system in vivo, and 
causing the consumption of coagulation factors, resulting 
in clinical anticoagulation. Fibrinogen clotting and fi-
brinolytic snake venom toxins exert a direct effect on the 
actual thrombus-forming protein, fibrinogen, but in varying 
ways. Fibrinogen may be split into fibrin and then degrada-
tion products, or it may be only partially split, leaving an 
ineffective form of fibrinogen circulating, the end result 
being an increased bleeding tendency. Snake venom inhibits 
platelet activity too, thus reducing their effectiveness in he-
mostasis [13, 14]. 
  Another study reported there is transient presence of an 
inhibitor to factors VIII, IX and XI in cases of tiger snake 
envenomation [15]. In our case, cobra toxin was probably 
the cause of development of factor VIII inhibitor, since the 
acquired factor VIII deficiency developed right after consum-
ing the cobra toxin, and we did not find any other possible 
cause of acquired factor VIII deficiency in this patient. 
Perhaps cobra toxin entered the blood stream through dam-
aged oral mucosa, and acted as factor VIII inhibitor. In order 
to make a clear connection between cobra toxin and acquired 
factor VIII deficiency, further evaluation about the effects 
of snake venom on individual coagulation factors is needed. 
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